Trafficking and localization studies of recombinant α1,3-fucosyltransferase VI stably expressed in CHO cells by Borsig, Lubor et al.
 1998 Oxford University Press
Glycobiology vol. 8 no. 3 pp. 259–268, 1998
259
Trafficking and localization studies of recombinant α1,3-fucosyltransferase VI
stably expressed in CHO cells
Lubor Borsig, Andreas G.Katopodis1, 
Benjamin R.Bowen1 and Eric G.Berger2
Institute of Physiology, University of Zürich, Winterthurerstrasse 190,
CH-8057 Zürich, Switzerland, and 1Novartis, Pharma A.G., Basel, Switzerland
Received on July 8, 1997; revised on September 15, 1997; 
accepted on September 24, 1997
2To whom correspondence should be addressed
Peripheral α1,3-fucosylation of glycans occurs by the action
of either one of five different α1,3-fucosyltransferases
(Fuc-Ts) cloned to date. Fuc-TVI is one of the α1,3-fucosyl-
transferases which is capable to synthesize selectin ligands.
The major α1,3-fucosyltransferase activity in human plasma
is encoded by the gene for fucosyltransferase VI, which pre-
sumably originates from liver cells. While the sequence,
chromosomal localization, and kinetic properties of Fuc-TVI
are known, immunocytochemical localization and trafficking
studies have been impossible because of the lack of specific
antibodies. Here we report on the development and charac-
terization of a peptide-specific polyclonal antiserum mono-
specific to Fuc-TVI and an antiserum to purified soluble
recombinant Fuc-TVI crossreactive with Fuc-TIII and Fuc-
TV. Both antisera were applied for immunodetection in stably
transfected CHO cells expressing the full-length form of this
enzyme (CHO clone 61/11). Fuc-TVI was found to be a
resident protein of the Golgi apparatus. In addition, more
than 30% of cell-associated and released enzyme activity was
found in the medium. Maturation and release of Fuc-TVI was
analyzed in metabolically labeled CHO 61/11 cells followed
by immunoprecipitation. Fuc-TVI occurred in two forms of
47 kDa and 43 kDa bands, while the secreted form was
detected as a 43 kDa. These two different intracellular forms
arose by posttranslational modification, as shown by pulse-
chase experiments. Fuc-TVI was released to the supernatant
by proteolytic cleavage as a partially endo-H resistant glyco-
form.
Key words: CHO cells/α1,3-fucosyltransferase Fuc-TVI/Golgi
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Introduction
The α1,3-fucosyltransferases (Fuc-Ts) constitute a family of
glycosyltransferases with a high degree of homology (Lowe,
1991). This family of enzymes encompasses five different
fucosyltransferases, named Fuc-TIII to Fuc-TVII (Goelz et al.,
1990; Kukowska-Latallo et al., 1990; Koszdin and Bowen, 1992;
Weston et al., 1992; Natsuka et al., 1994; Sasaki et al., 1994).
Fuc-Ts differ in their capacity to transfer L-fucose to oligo-
saccharide acceptors thereby contributing to the formation of the
various Lewis antigens (Mollicone et al., 1992).
While the expression of Fuc-TVII correlates with the synthesis
of selectin ligands (Smith et al., 1996; Maly et al., 1996), the
Fuc-TIV enzyme is predominantly expressed in myeloid cells
with a substrate preference toward neutral lactosamine acceptors
(Mollicone et al., 1992; Clarke et al., 1996). Three other members
of this family, Fuc-TIII, Fuc-TV, and Fuc-TVI, have a very high
degree of homology. They are syntenically arranged on chromo-
some 19 as a multigene family (Nishihara et al., 1993). Their
detailed acceptor specificity was recently delineated to some
extent by various chimeric constructs between Fuc-TIII and
Fuc-TVI (Legault et al., 1995) or Fuc-TIII and Fuc-TV1995 (Xu
et al., 1996). These experiments showed the unexpected result
that the relative preference of Fuc-TIII for type I acceptors
(Lacto-N-biose I) can be abrogated by replacing a segment of
only 50 amino acids located in the hypervariable region
(AA102–150) with the corresponding segment of Fuc-TVI
(Legault et al., 1995). In contrast, the preference of Fuc-TIII for
type I acceptors was found to be determined also by an additional
region of AA73–120 as observed by domain swapping between
Fuc-TIII and Fuc-TV (Xu et al., 1996). Thus, the differences in
acceptor substrate utilization among Fuc-TIII, -V, and -VI in vitro
and the predominant preference for type II acceptors (N-acetyl-
lactosamine) of Fuc-TVI and V suggests different in vivo
functions for these enzymes. Fuc-TVI was initially described as
the plasma-type enzyme, because its substrate specificity
resembles that of a fucosyltransferase purified from plasma
(Mollicone et al., 1992; Sarnesto et al., 1992). It was
subsequently demonstrated that a missense mutation in Fuc-TVI
gene is responsible for the deficiency in plasma activity observed
in some Java families (Mollicone et al., 1994). This observation
demonstrates that the α1,3-fucosyltransferase activity in human
plasma is indeed encoded by the Fuc-TVI gene. Moreover, on the
basis of deficient fucosylation of liver glycoproteins its tissue
origin has been proposed to be the hepatocytes (Brinkman-Van
der Linden et al., 1996).
Fucosyltransferases like other glycosyltransferases are resi-
dent membrane proteins of the endoplasmic reticulum and the
Golgi apparatus. Those associated with the Golgi apparatus are
type II proteins containing an N-terminal cytoplasmic region, a
transmembrane domain, an extended stem region, and a large
catalytic domain at the C-terminus. Soluble forms of some of
them have been found in milk, serum, and other body fluids (for
review, see Paulson and Colley, 1989). Proteolytic conversion of
β1,4-galactosyltransferase was observed upon release from HeLa
cells (Strous and Berger, 1982). Also some cloned enzymes have
been reported to be released from transfected cells (Larsen et al.,
1989; Jaskiewicz et al., 1996; Costa et al., 1997). Recently,
conversion to soluble forms of three endogenously expressed
glycosyltransferases was investigated in more detail. In the case
of β1,4-galactosyltransferase (Masri et al., 1988) and O-linked
N-acetylgalactosaminyltransferase (Homa et al., 1993) the cleav-
age site suggested serine proteases and for α2,6-sialyltransferase
the cleavage occurs by action of a cathepsin-like protease
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Fig. 1. (A) Scheme of the primary structures of three homologous human α1–3 Fuc-Ts. Fucosyltransferases are type II membrane proteins with a short N-terminal
cytoplasmic tail (left side), a single transmembrane domain (thick bars), a stem region containing potential N-glycosylation sites (stick figures) and the C-terminal
luminal part involved in catalytic activity (right side). Amino acid sequence identities were determined by comparison of Fuc-TVI with Fuc-TV and Fuc-TIII.
Different or missing residues are indicated with solid bars or shadowed area, respectively. The peptide (PEP6B) and soluble rFuc-TVI expressed in CHO cells
(OLI) used for immunization, respectively, are indicated. (B) Coomassie staining of purified srFuc-TVI used as antigen for the induction of the OLI antiserum.
rFuc-TVI was purified as described in Materials and methods. (C) Immunoblotting of srFuc-TVI with OLI antibodies. rFuc-TVI (1); rFuc-TVI treated with
PNG-ase F (2); rFuc-TVI treated with endo-H (3). In each lane, 1 µg of pure srFuc-TVI was used.
(Weinstein et al., 1987). Little is known with respect to
intracellular transport and trafficking of fucosyltransferases. It
seems likely that Fuc-TVI as the major fucosyltransferase activity
in plasma carries some distinct features with respect to release. To
investigate such aspects, we first raised monospecific antibodies
to recombinant Fuc-TVI and cloned stably transfected Chinese
hamster ovary (CHO) cells expressing a full-length form of this
enzyme. Here we report on localization, intracellular transport
and release of Fuc-TVI.
Results
Production and purification of soluble recombinant
Fuc-TVI (srFuc-TVI)
The D6 clone produced consistently 13–15 U/l of fucosyl-
transferase activity, and the pooled supernatants were kept frozen
without any detectable loss of activity. Recovery at the ion
exchange step was about 75%, some activity being lost in the
flowthrough. To achieve maximum binding to the SP-Sepharose
column it was important to lower the ionic strength of the
supernatant. Recovery from the GDP-hexanolamine column was
consistently almost 100% and the eluate displayed a single band
by SDS/PAGE analysis (Figure 1B). Using the Bio-Rad protein
assay dye, the specific activity of the final purified enzyme was
found to be 14 U/mg. Amino terminal sequencing of the purified
enzyme by Edman degradation gave no signal, indicating a
blocked amino terminus. After digestion with trypsin, several
peptides were subjected to Edman degradation and, as expected,
all gave sequences corresponding to portions expected from the
fucosyltransferase VI cDNA sequence (Koszdin et al., 1992).
Characterization of antibodies
To elicit specific polyclonal antisera to α1,3-fucosyltransferase
VI (Fuc-TVI), we followed two different strategies. Because of
the extensive homology of the α1,3-fucosyltransferase family
(Figure 1A), we selected an amino acid stretch located in the stem
region of Fuc-TVI with lowest similarity to the closely related
Fuc-TV. This peptide stretch designated PEP6B was synthesized
by a solid-phase method, coupled to hemocyanin, and used as an
antigen. The second antiserum was produced against purified
srFuc-TVI derived from CHO cells (see above). The half-
maximum response to PEP6B (Figure 2A) as well as to
srFuc-TVI (Figure 2B) corresponded to a titer of 1/80 and 1/2000,
respectively. The antiserum to PEP6B recognized srFuc-TVI,
while the antiserum to srFuc-TVI did not recognize the PEP6B
peptide. The antiserum to PEP6B peptide is further designated
PEP6B antiserum and the antiserum to srFuc-TVI OLI antiserum.
To ascertain the specificity of our antisera to Fuc-TVI, cell
lysates from stably transfected CHO cells expressing one of the
Fuc-Ts (Fuc-TVI, Fuc-TV, or Fuc-TIII) or COS cells transiently
transfected with respective plasmids were subjected to immuno-
blotting with OLI antiserum and PEP6B antiserum, respectively
(Figure 3A,B). The PEP6B antiserum was revealed to be
monospecific to Fuc-TVI. Besides Fuc-TVI, the OLI antiserum
also recognized Fuc-TV and Fuc-TIII. To further analyze our
antisera, activity of recombinant Fuc-TVI from CHO cells was
subjected to a neutralization experiment (Figure 3C). The OLI
antiserum was able to inhibit activity at least by 80%, whereas
PEP6B was ineffective.
Fuc-TVI localization in the Golgi apparatus
To determine the steady-state distribution of Fuc-TVI expressed
in stably transfected CHO cells (CHO 61/11), we subjected these
cells to an indirect immunofluorescence microscopy (Figure 4) in
Expression of Fuc-TVI in CHO cells
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Fig. 2. ELISA of antisera to rFuc-TVI and to peptide PEP6B. (A) The plates
were coated with peptide PEP6B. Binding curve of antiserum to PEP6B
(diamonds), and PEP6B preimmune serum (squares). (B) The plates were
coated with rFuc-TVI. Binding curve of OLI antiserum (diamonds), and OLI
preimmune serum (squares). Binding curve of antiserum to PEP6B
(triangles). Arrows indicate the titer as defined by half-maximum binding.
permeabilized cells, as described in Materials and methods. OLI
antibodies localized Fuc-TVI to the Golgi apparatus (Figure 4E)
while preimmune serum (Figure 4C) or mock transfected cells
stained with antiserum (Figure 4A) showed background staining
only. Golgi location of Fuc-TVI was further confirmed by double
immunofluorescence staining with anti-Giantin antibodies
(Linstedt et al., 1993; Figure 4G,H). The Fuc-TVI staining
pattern obtained with PEP6B antibodies differed considerably
from that of OLI antibodies. PEP6B antibodies produced a typical
ER pattern which was observed in a small number of cells only;
these cells exhibited no Golgi staining (Figure 4F). These results
demonstrated binding of the peptide antiserum to recombinant
Fuc-TVI since neither preimmune serum (Figure 4D) nor
immune serum applied to mock transfected cells produced any
staining (Figure 4B). An ER like signal was also observed in some
cells stained with OLI antibodies (Figure 4E) probably due to
variation of expression level which may cause ER retention.
Absence of Golgi staining with PEP6B antibodies indicates that
the peptide epitope might become inaccessible due to post-
translational modification or folding. In order to prove this
possibility, CHO 61/11 were subjected to in situ denaturation with
6 M guanidinium-HCl prior to adding PEP6B antibodies and
corresponding second antibodies (Figure 5). In fact, cells treated
with guanidinium-HCl produced a strong signal in the Golgi
apparatus using PEP6B antibodies (Figure 5B). Thus, recognition
of Fuc-TVI by PEP6B antibodies was restricted to an unfolded
form of the enzyme. Subsequent folding of the antigen prevented
these antibodies from binding to their epitopes on Fuc-TVI
located in the Golgi apparatus or further downstream in the
secretory pathway.
Fuc-TVI in CHO 61/11 cells is secreted to the medium
Maturation of Fuc-TVI in CHO 61/11 cells was analyzed by
metabolic labeling and immunoprecipitation. Lysates of CHO
61/11 cells continuously labeled for 1 h were immunoprecipitated
with OLI antibodies and analyzed on SDS/PAGE gel (Figure 6).
Fuc-TVI exhibited a pattern of two major bands with molecular
masses of 47 kDa and 43 kDa (lanes 2 and 3) and two minor bands
of 40 kDa and 37.5 kDa, both representing putative degradation
products. No shift was observed after neuraminidase treatment
(lane 4). PNG-ase F treatment produced a preponderant band of
Fig. 3. Characterization of antibodies by immunoblotting and neutralization.
Immunoblotting of cell lysates from stably transfected CHO cells (A) and
transiently transfected COS cells (B) with pcDNAI alone (M), pcFuc-TIII
(III), pcFuc-TV (V), and pcFuc-TVI (VI). (A) Immunoblotting with OLI
antiserum showing crossreactivity with Fuc-TIII and Fuc-TV. (B)
Immunoblotting with PEP6B antiserum showing specificity only to Fuc-TVI
and putative degradation products. Both immunoblots were carried out as
described previously (Watzele et al., 1991). (C) Inhibition of Fuc-TVI
activity using OLI and PEP6B antisera, respectively. Fuc-TVI activity was
assayed in lysates of CHO 61/11cells as described in Materials and methods
using LacNAc as an acceptor substrate. 1, Control assay mixture of 50 µl
supplemented with 20 µl of H2O. 2, As in 1, with 20 µl of preimmune serum
(PIS). 3, As in 1, with 10 µl of PIS and 10 µl of the respective antiserum. 4,
As in 1, with 20 µl of the respective antiserum.
36.5 kDa and an additional band of 38.5 kDa (lane 6).
Endoglycosidase-H (endo-H) treatment changed the 43 kDa to
L.Borsig et al.
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Fig. 4. Immunofluorescence microscopy of stably transfected CHO cells
with Fuc-TVI (61/11). Cells were grown and subjected to
immunofluorescence labeling as described in Materials and methods. (A)
and (B), Control CHO cells stably transfected with pcDNAI (Mock) stained
with OLI antiserum and PEP6B antiserum, respectively. (C) and (D), CHO
61/11 cells stained with OLI preimmune serum and PEP6B preimmune
serum, respectively. (E) and (F), CHO 61/11 cells stained with affinity
purified OLI antibodies and PEP6B antibodies, respectively. (G) and (H),
Double staining of CHO 61/11 cells with OLI antibodies (G) and
anti-Giantin antibodies (H). Details are given in Material and methods. Scale
bar, 20 µm.
36.5 kDa and the 37.5 kDa to 31 kDa forms, respectively. In
addition, it gave rise to a minor form of 42.5 kDa partially
sensitive to endo-H (lane 5). Fuc-TVI has four potential
N-glycosylation sites. In case of occupancy of all four potential
N-glycosylation sites, a shift of at least 2 kDa per site can be
expected, which is in agreement with the observed shift.
However, the size of 36.5 kDa form is not compatible with a
full-length nonglycosylated translation product of Fuc-TVI,
which is estimated to be 42 kDa. To further analyze the different
Fig. 5. PEP6B antibodies recognize Fuc-TVI in the Golgi apparatus of CHO
61/11 cells after in situ denaturation. (A) CHO 61/11 cells stained with
PEP6B antibodies. (B) and (C), CHO 61/11 cells stained with PEP6B
antibodies after denaturation with 6 M guanidinium-HCl (C1). Interference
contrast picture of the cells shows C2. For details, see Materials and
methods. Scale bars: (A) and (B) 20 µm; (C) 10 µm.
forms obtained by continuous labeling, pulse-chase labeling was
carried out (Figure 7A). The 43 kDa band (no chase), correspon-
ding to the core glycosylated enzyme, partially shifted to 47 kDa
after 30 min, and became preponderant after 2 h. The 43 kDa and
37.5 kDa forms, respectively, were sensitive to endo-H treatment
(no chase) and shifted to a 36.5 kDa form and a 31 kDa form,
respectively, as already depicted on Figure 6 (lane 5). The 47 kDa
band represented a partially endo-H sensitive band which shifted
to a 42.5 kDa band (60 min chase). The shift of 4.5 kDa may
correspond to cleavage of two endo-H sensitive N-linked glycans.
After 120 min of chase the 36.5 kDa band decreased and the
42.5 kDa band became dominant. The chase medium was also
subjected to immunoprecipitation (Figure 7B). Fuc-TVI was
secreted into the medium after 2 h as a 43 kDa molecule. Since
secretion appeared to be associated with a reduction of the
molecular size by 4 kDa, we investigated this conversion further.
CHO 61/11 cells were metabolically labeled and chased for 4 h.
The secreted form of Fuc-TVI was immunoprecipitated and
analyzed (Figure 8A). The 43 kDa band shifted upon PNG-ase F
treatment to a band of 33.5 kDa (lane 4). Endo-H treatment
produced a band of 41 kDa, which indicates that secreted form is
also partially endo-H sensitive (lane 3). Neuraminidase treatment
showed a discrete band of 43 kDa band (lane 2) in comparison to
a rather diffuse band of a nontreated preparation (lane 1). The
secreted and the intracellular form of Fuc-TVI were compared
under reducing or nonreducing conditions (Figure 8B). The
intracellular form under nonreducing condition yielded homo-
dimers of about 94 kDa and monomers, but the secreted form
appeared only as a monomer. In addition, immunoblotting also
Expression of Fuc-TVI in CHO cells
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Fig. 6. Metabolic labeling of CHO 61/11 cells and immunoprecipitation with
OLI antibodies. Cells were grown, labeled for 1 h, and immunoprecipitated
as described in Materials and methods. Metabolically labeled cell lysates
were immunoprecipitated and glycosidase treated as follows: lane 1, OLI
preimmune serum; lane 2, OLI immune serum; lane 3, affinity purified OLI
antibodies; lane 4, OLI antibodies, neuraminidase; lane 5, OLI antibodies,
endo-H; lane 6, OLI antibodies, PNG-ase F.
revealed a clear difference between the intracellularly matured
form of 47 kDa and the secreted form of 43 kDa (Figure 8C).
Table I. Fuc-TVI activity in the cell lysates of CHO cells and in the medium
Activity of α1,3-fucosyltransferase VI
Relative activitya 
(%)
Activity 
(nmol/min/mg prot.)
Acceptor Lysate Medium Mock Lysate
N-Acetyllactosamine 100 100 0 2.93
Lacto-N-biose I 0.3 0.2 0 0.011
2-Fucosyllactose 4.5 4.3 0 0.133
α2,3-Sialyllactosamine 131 121 0 3.85
Total Fuc-TVI 
activity distribution 2 : 1
aA value of 100% was assigned to the specific activities of enzyme with the
acceptor N-acetyllactosamine. Relative activities for each of the other
acceptors are listed as the ratio of their respective activities to the activity
observed with N-acetyllactosamine..
To define the distribution of Fuc-TVI the enzymatic activity
was measured in the cell lysate and in the medium of CHO 61/11
cells after 48 h of proliferation (Table I). The activity pattern of
Fuc-TVI with four different acceptors was in agreement with
published results (Cameron et al., 1995). No difference was
observed in acceptor specificity of secreted Fuc-TVI form in
comparison to the intracellular form. The enzyme activity found
in the medium accounted to 30% of combined cell-associated and
released enzyme.
Determination of Fuc-TVI molecular weight
The N-deglycosylated form of Fuc-TVI appeared on SDS/PAGE
as a 36.5 kDa form instead of the expected 42 kDa. Therefore, we
analyzed the intracellular form further. The pulse-chase experi-
ment (see above) already indicated that early Fuc-TVI forms (no
chase) had 43 kDa, which shifted to 36.5 kDa upon endo-H
treatment. In these early steps after translation no proteolytic
cleavage should be expected. To ascertain that Fuc-TVI is
expressed as a full length enzyme without any proteolytical
processing after translation, we investigated the integrity of
Fuc-TVI. Thus, we prepared a cell homogenate and centrifuged
it by 100,000 × g to separate the membrane fraction. An aliquot
of homogenate, supernatant, and membrane pellet was analyzed
on SDS/PAGE gel and immunoblotted with OLI antibodies
(Figure 9). All of the immunoreactive enzyme was associated
with the pellet, suggesting maintenance of membrane association.
In addition, enzyme assay determinations showed that all the
activity was also associated with the pellet, while in the
supernatant less than 4% was detected (data not shown). Further,
sodium carbonate treatment of the pellet did not extract any
detectable Fuc-TVI as determined by immunoblot or by activity
measurements (data not shown). This experiment showed that the
Fuc-TVI present in CHO cells was membrane-associated and,
therefore, can be assumed to correspond to the full length form.
Moreover, in the presence of tunicamycin Fuc-TVI expressed in
COS cells also migrated as a 36.5 kDa (not shown). In vitro
translation of Fuc-TVI encoding cDNA also produced a 36.5 kDa
form (data not shown). Thus, the molecular size determination of
Fuc-TVI by SDS/PAGE gel seemed to underestimate its putative
molecular size of 42 kDa.
To support this explanation we analyzed the glycosylation of
srFuc-TVI by immunoblotting (Figure 1C). Native srFuc-TVI
displayed a band of 43 kDa. Endo-H treatment generated a
40 kDa band showing partial sensitivity to endo-H even of the
secreted form of Fuc-TVI and PNG-ase F treatment generated a
band of 33 kDa. Since the expected molecular weight of
srFuc-TVI calculated from the amino acid sequence of the cloned
enzyme is 36 kDa, it is possible that srFuc-TVI migrates
differently as the calibration standards on SDS/PAGE. To
confirm this we analyzed the deglycosylated protein by MALDI
mass spectrometry. This analysis determined the N-deglycosy-
lated srFuc-TVI (after PNG-ase F treatment) to be of 40 ± 1 kDa.
Thus, the observed higher mobility of N-deglycosylated srFuc-T
VI on SDS/PAGE (yielding 33 kDa) underestimates its molecular
weight, which is predicted to be 36 kDa and shown to be 40 kDa
by MALDI mass spectrometry. This difference of 4 kDa may be
due to O-glycosylation. A similar difference in mobility is
assumed to explain the discrepancy between the 36.5 kDa of the
N-deglycosylated full length form of Fuc-T VI and the expected
42 kDa (see above).
L.Borsig et al.
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Fig. 7. Pulse-chase labeling of CHO 61/11 cells. (A) Pulse was for 10 min, and chase times were as indicated. For every time point the
immunoprecipitate was treated with endo-H and PNG-ase F (not shown). (B) For every time point the secreted Fuc-TVI was immunoprecipitated from
medium. For details, see Materials and methods.
Discussion
This work represents one of the approaches to investigate the
family of α1,3-fucosyltransferases and, more specifically, aims at
understanding localization and intracellular transport of Fuc-TVI.
The main problem in addressing this topic is the homology of
Fuc-TIII, -V, and -VI, which requires extensive antibody
specificity testing to insure monospecificity. Thus, two different
antibodies were raised against Fuc-TVI. As expected, OLI
antibodies produced against recombinant soluble Fuc-TVI also
recognized Fuc-TIII and Fuc-TV. However, PEP6B antipeptide
antibody was monospecific to Fuc-TVI. The recognition of
Fuc-TVI by this antibody was restricted to an unfolded protein.
The PEP6B peptide stretch is closely located to the catalytical
domain of the enzyme; thus, correct folding might prevent
recognition by this antibody. Recent studies showed that this
particular region which includes the PEP6B peptide stretch plays
a critical role in substrate specificity differences between the two
enzymes, Fuc-TIII and Fuc-TVI, both having almost identical
C-terminal portions (Legault et al., 1995). The lack of an effect
of PEP6B antibodies to fucosyltransferase activity and the
inability to immunoprecipitate an active enzyme form (not
shown) support these observations.
By immunofluorescence microscopy using both antibodies
(PEP6B and OLI) Fuc-TVI was localized to the Golgi apparatus.
Similar results have been obtained with Fuc-TV in transiently
transfected COS cells (Borsig et al., 1996). These observations
are also in agreement with the general accepted scheme for the
synthesis of complex carbohydrates, which predicts that α1–3
fucosyltransferases would be localized to a late Golgi com-
partment or TGN, because of their participation in termination of
glycan biosynthesis (Lowe, 1991).
The CHO 61/11 cells stably transfected with the full-length
membrane-bound form of human Fuc-TVI unexpectedly secreted
considerable amounts of a soluble form of the active enzyme into
the medium (more than 30% of the total enzyme activity, which
was measured after 48 h proliferation). Secretion of glycosyltrans-
ferases from transfected cells has been reported also for other
recombinant enzymes such as Fuc-TIII expressed in BHK-21 cells
(Costa et al., 1997) or β1,4-N-acetylgalactosaminyltransferase in
CHO cells (Jaskiewicz et al., 1996). In line with results analyzing
the cleavage site of endogenously released glycosyltransferases
(see Introduction), a common mechanism of endoproteolytic
cleavage preceding secretion may exist. In the case of β1,4-galac-
tosyltransferase (Masri et al., 1988) and O-linked N-acetylgalacto-
saminyltransferase (Homa et al., 1993) a serine protease cleavage
site was identified. Another cleavage site for a cathepsin D-like
protease was identified for α2,6-sialyltransferase (Weinstein et al.,
1987) and for β1,4-N-acetylgalactosaminyltransferase (Jaskiewicz
et al., 1996). Bulk secreted form of srFuc-TVI (Figure 1B)
represents the very same form of 43 kDa as the form identified after
metabolic labeling and immunoprecipitation of Fuc-TVI released
from CHO 61/11 cells (Figure 8A). This observation suggests that
cleavage of Fuc-TVI and its release as a soluble form occurred
within the same region where srFuc-TVI was cleaved. A closer
look at the sequence of the stem region and comparison with
already known protease cleavage sites indicates a possible
cathepsin D–like protease site. This indication needs further
experimental support. The question in which compartment of the
secretory pathway the soluble form of glycosyltransferase is
Expression of Fuc-TVI in CHO cells
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Fig. 8. Immunoprecipitation of secreted form of Fuc-TVI from medium. (A)
CHO 61/11 cells were pulsed for 1.5 h and chased for 4 h. Secreted Fuc-TVI
was immunoprecipitated from medium with OLI antibodies and treated as
follows: lane 1, without treatment; lane 2, neuraminidase treatment; lane 3,
endo-H treatment; lane 4, PNG-ase F treatment. (B) Fuc-TVI
immunoprecipitates from cell lysate (C) and from medium (M) were
separated on a SDS–PAGE gel under reducing condition with 5%
β-mercaptoethanol (+βME) and under nonreducing condition (-βME). (C)
Immunoblotting of Fuc-TVI. Cell lysate (C), medium (M).
generated remains unanswered. So far this problem has only been
solved in the case of α2,6-sialyltransferase showing the solubiliz-
ation in the Golgi fraction (Weinstein et al., 1987). In the case of
Fuc-TVI a similar mechanism leading to a soluble form occurring
in the Golgi apparatus can be expected. Pulse-chase labeling and
immunoprecipitation clearly showed that the intracellular form of
Fuc-TVI is mostly presented as homodimers and the secreted form
only as monomers. This is in good agreement with a proposed
model of oligomerization, which leads to retention of glycosyl-
transferases in the Golgi apparatus (Nilsson et al., 1993). In
contrast to a soluble form of β1,4-N-acetylgalactosaminyltransfer-
ase which was secreted in the form of homodimers (Jaskiewicz
et al., 1996), Fuc-TVI was detected only as monomers. Homo-
dimers of Fuc-TVI can be formed by cystein residues present in the
cytoplasmic and most probably in the transmembrane domain. A
similar phenomenon of dimerization by cysteins located in the
transmembrane domain followed by retention in the Golgi
apparatus has been described previously for β1,4-galactosyltrans-
ferase (Yamaguchi and Fukuda, 1995).
The role of released soluble glycosyltransferases remains still
unanswered. The catalytic activity of these enzymes is strictly
dependent on the presence of acceptors and substrates. Little is
known about their access to such an environment, and whether the
enzymes can be catalytically active. Soluble glycosyltransferases
may have at least certain sugar binding properties. Fuc-TVI
encodes an enzyme which is released to the plasma (Mollicone
Fig. 9. Immunoblotting of Fuc-TVI in cell homogenate and a 100,000 × g
pellet. CHO 61/11 cell lysate was homogenized and an aliquot was frozen
and thawed twice prior to centrifugation at 100,000 × g for 1 h at 4C.
Homogenized cells (H), supernatant (S), and membrane pellet (P) were taken
for SDS–PAGE and immunoblotted with OLI antibodies..
et al., 1992). The major part of plasma α1,3-fucosyltransferase
activity is attributed to this enzyme (Brinkman-Van der Linden
et al., 1996). Our work is a first step to better understand the
process of Fuc-TVI release into the medium. Further work on
Fuc-TVI in natively expressing cells will help to understand the
action of soluble and cell-surface α1,3-fucosyltransferase VI.
Materials and methods
Cell culture and transfection
CHO wt. cells were obtained from Dr. Renner, ETH Zürich, and
were grown in HAM’s medium supplemented with 10% fetal calf
serum; for transfection Optimem medium was used; and for
metabolic labeling MEM Select-Amin-Kit was used (all media
were from Gibco BRL, Grand Island, NY). CHO cells stably
transformed with pcFuc-TVI, pcFuc-TV, and pcFuc-TIII, re-
spectively, were prepared (see below). Cells were cotransfected
by lipofectamine with the respective pcDNAI constructs and
pSV2Neo (Clontech, Palo Alto, CA) in a ratio of 6:1 and on day
3 after transfection G418 was added to the medium with final
concentration of 800 µg/ml. Clones were obtained by limiting
dilution and tested for fucosyltransferase activity. CHO/Fuc-TVI
clone is further referred to as CHO 61/11. COS-7 cells were
obtained from ATCC (Rockville, MD) and grown in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 10% fetal
calf serum; for transfection and metabolic labeling the same
media as for CHO were used.
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Constructs in pcDNAI for cell transfection
The cDNAs encoding Fuc-TV and Fuc-TVI were isolated from
A-431 and HL-60 cell lines, respectively, as described previously
(Koszdin et al., 1992). cDNAs encoding full length forms of
fucosyltransferase in pcDNAI designated pcFuc-TVI for Fuc-
TVI, pcFuc-TV for Fuc-TV, and pcFuc-TIII for Fuc-TIII were
constructed as described previously (Borsig et al., 1996). COS
cells were transiently transfected as described previously (Borsig
et al., 1996).
Peptide synthesis and coupling
Specific peptide was synthesized using standard Fmoc (N-[9-fluore-
nyl]methoxycarbonyl) chemistry on the solid phase peptide synthe-
sizer (model 430A, Applied Biosystems, Foster City, CA). After
deprotection, the synthesized peptide Pep6B (REVMYNP-
SAQLPRSPRR) was purified by gel filtration on Biogel P-2
(Bio-Rad, Hercules, CA). Correct molecular weight was confirmed
by fast atom bombardment mass spectrometry. For antibody
production, peptide was coupled to hemocyanin using glutaralde-
hyde (Borsig et al., 1996) and used for immunization.
Expression and purification of recombinant soluble
Fuc-TVI from CHO cells
The method of Colley and Paulson (Colley et al., 1989) was used
to prepare an expression construct for soluble fucosyltransferase-
VI. A cassette containing the γ-interferon signal sequence was
prepared from the following oligonucleotides: IFN10 (5′-GGA
AGC TTG ACC ACC ATG AAA TAT ACA AGT TAT ATC
TTG GCT TTT CAG CTC TGC-3′) and IFN11 (5′-TGG GTC
CTG GCA GTA ACA GCC AAG AGA ACC CAA AAC GAT
GCA GAG CTG AAA AGC-3′). Oligonucleotides IFN10 and
IFT11 were amplified by PCR using primers 5′-g (5′-ATA CGG
AAG CTT GAC CAC CA-3’) and 3′-g(5′-CTA CCC GGG GTC
CTG GCA GTA A-3′). The product was digested with HindIII
and SmaI restriction endonucleases and, along with a fragment of
the Fuc-TVI cDNA (Koszdin et al., 1992) truncated at Leu63,
was cloned into pCDNA-Amp (Invitrogen). The resulting
expression vector, γFT-VI/pCDNA-Amp, was sequenced to
confirm that the expression construct would direct the expression
of the following fusion protein: MKYTSYILAFQLCIVLGSLG
CYCQDP /LILL... (gamma interferon signal sequence/Fuc-TVI
63–359).
The γFT-VI/pCDNA-Amp vector was transfected into COS-7
cells, and supernatants from the cells were harvested and were
demonstrated to have significant fucosyltransferase activity. The
1.0 kb HindIII-BamHI fragment from γFT-VI/pCDNA-Amp
corresponding to the coding sequence of the fusion protein was
subcloned into pREP9 (Invitrogen). This vector, γFT-VI/pREP9,
was electroporated into CHO cells. After selecting for resistance
to G418 (0.4 mg/ml), clonal lines were isolated by limiting
dilution. A particular clone, D6, gave high levels of expressed
protein and was used in all subsequent work.
Production and purification of soluble Fuc-TVI
CHO cells (clone D6) in MEMα (Gibco) containing 5% FBS and
0.4 mg/ml G418 were seeded in multilevel T flasks (Nunc). After
the flasks became confluent the medium was changed to 3% FBS,
with no added G418. Supernatants were harvested every second
day and kept frozen. Pooled supernatants (about 3–5 l at a time)
were concentrated on a S10Y30 spiral-wound membrane car-
tridge (Amicon) to about 10% of the original volume. The
concentrate was diluted 1/3 with 20 mM Na cacodylate pH 6.5,
and reconcentrated. All following steps were performed at 4C.
The final concentrate was loaded on a 50 ml column of
SP-Sepharose Fast Flow (Pharmacia) equilibrated with 20 mM
sodium cacodylate pH 6.5 (loading buffer) at a flow of 5 ml/min.
After loading, the column was washed with 200 ml of loading
buffer and subsequently with 200 ml of loading buffer containing
50 mM NaCl. The fucosyltransferase activity was eluted with
100 ml of loading buffer containing 500 mM NaCl and 10%
glycerol. The eluate was concentrated to about 10% of total
volume by ultrafiltration on a YM30 membrane (Amicon).
A 6 ml fucosyltransferase affinity column was prepared by
attaching 40 mg of GDP-hexanolamine to 3 g activated CH
Sepharose 4B (Pharmacia) according to the manufacturer’s
instructions and finally equilibrated with 20 mM sodium
cacodylate pH 6.5, 10% glycerol, 20 mM Mn2+ (affinity buffer).
After ion exchange chromatography, the concentrated fucosyl-
transferase eluate was diluted with an equal volume of affinity
buffer and loaded on to the GDP-hexanolamine column at a flow
rate of 0.5 ml/min. The column was subsequently washed with
100 ml of affinity buffer containing 500 mM NaCl in order to
remove nonspecifically bound proteins and then with 20 ml 20
mM sodium cacodylate pH 6.5, 10% glycerol, 500 mM NaCl.
The fucosyltransferase activity was eluted with 50 ml 20 mM
sodium cacodylate pH 6.5, 20% glycerol, 500 mM NaCl, 10 mM
EDTA, 10 mM GDP. The final eluate was concentrated to a final
volume of a few ml, exchanged two times against 20 ml of 20 mM
sodium cacodylate, 20% glycerol, 200 mM NaCl, 0.02% Na
azide and stored at 4C.
Antibody production and purification
Polyclonal sera against peptide antigen Pep6B, and srFuc-TVI
were raised as described previously (Borsig et al., 1996). The
antibodies were affinity-purified by passing over columns of
immobilized peptide on Affi-Gel 10 support (Bio-Rad) and eluted
as described previously (Borsig et al., 1996).
ELISA
Nunc immunoplates Maxisorp (Gibco) were coated with 0.5 µg/ml
of peptide or 1 µg/ml of srFuc-TVI and used as described
previously (Watzele et al., 1991).
Confocal laser scanning double immunofluorescence
microscopy
CHO cells and COS-7 cells were fixed and permeabilized as
described previously (Borsig et al., 1996). As first antibodies
PEP6B antibodies, OLI antibodies, or anti-Giantin mAB G1/133,
kindly provided by Prof. H. P. Hauri, Biocenter Basel (Linstedt
et al., 1993), were used. Fluorescein isothiocyanate (FITC) and
Texas red (TR)-conjugated secondary antibodies were obtained
from Dako (anti-mouse Ig) and Organon (anti rabbit Ig).
Embedding medium containing 5% n-propyl-gallate in 30 mM
Tris–HCl, pH 9.5 with 70% of glycerol for mounting of
coverslips was used. In case of in situ denaturation of CHO 61/11
cells, 6 M guanidinium HCl was added on the coverslips prior to
adding of antibodies. After 30 min treatment cells were washed
six times for 5 min with PBS, and then first and second antibodies
were used. Immunofluorescence images were taken on a Leica
microscope using dual fluorescence mode for Texas red and
FITC. Single fluorescence images or extended focus projections
were generated using the Imaris software (Bitplane, Zürich,
Switzerland).
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Metabolic labeling
CHO cells were plated on 100-mm Petri dishes and grown till 80%
confluency. Before labeling, cells were washed with PBS and
incubated for 15 min at 37C in methionine, cysteine-free MEM
medium, and then labeled for 1 h at 37C (continuous labeling) or
10 min (pulse/chase) with 0.4 mCi/plate [35S] methionine
(EXPRE35S35S methionine, cysteine labeling mix, NEN/ Du Pont,
Wilmington, DE). Cells were washed or chased with complete
DMEM medium and two times with PBS. In case of CHO 61/11
cells labeling for secreted form of Fuc-TVI, cells were labeled for
1.5 h and chased in complete medium for 4 h. Cells were scraped
off the culture dishes in 10 ml ice-cold PBS containing protease
inhibitors per ml: 1 µg antipain, 1 µg aprotinin, 1 µg benzamidine,
0.5 µg leupeptin, 1 µg pepstatin A, 0.2 mM PMSF), and collected
by centrifugation at 1500 × g for 5 min.
Immunoprecipitation and electrophoresis
Cells were lysed in 1 ml PBS containing 1% (w/v) Triton X-100
for 30 min at 4C while rocking. Lysates were cleared by
centrifugation for 10 min at 15,000 × g at 4C and preabsorbed
for 1 h at 4C with 100 ml suspended protein A–Sepharose
(Pharmacia) in 10 ml buffer A (PBS, 1% (w/v) Triton X-100).
Protein-A beads were spun down and antiserum or purified
antibodies bound to 100 ml suspended protein A–Sepharose were
added to the precleared lysate, respectively. Immunoprecipitation
was carried out overnight by 4C while rocking. The Sepharose
beads were washed three times with buffer A and three times with
PBS, after which they were boiled for 5 min in reducing
SDS–PAGE sample buffer. For PNG-ase F and endo-H treatment,
30 µl of 0.5% SDS, 1% β-mercaptoethanol in water was added
to the washed beads and boiled for 10 min. After cooling, beads
were spun down. The supernatant was adjusted to 1% NP-40
(w/v) and incubated for 16 h at 37C either with 500 U of
PNG-ase F (NEB, Beverly, MA) or with 50 U of endo-H (NEB).
For neuraminidase treatment, to the washed beads 30 µl of 50 mM
sodium citrate, pH 4.5, protease inhibitors (see above) and 50 U
of neuraminidase (NEB) were added and incubated for 16 h at
37C. The reaction was stopped by adding an equal volume of 2×
SDS–PAGE sample buffer and boiled for 5 min. Immunoprecipi-
tated proteins were separated by SDS–PAGE on a 10% acryla-
mide gel. After electrophoresis, gels were soaked in 50%
methanol, 10% acetic acid and dried, and dried gels were exposed
to FUJI X-RAY films.
Immunoblotting
Cell lysates were prepared in 1% (w/v) Triton X-100 in PBS.
Electrophoresis on 10% SDS/PAGE gel and following immuno-
blotting was carried out as described previously (Watzele et al.,
1991). Nitrocellulose membranes were incubated first with
affinity purified PEP6B antibodies or OLI antibodies (1:200)
followed by goat anti rabbit-horseradish peroxidase (1:5000) and
stained with ECL developing kit according to the manufacturer’s
instructions (Amersham).
Fucosyltransferase assay
Cell extracts containing 1% Triton X-100 were prepared from
CHO cells as described previously (Kukowska-Latallo et al.,
1990). Protein concentrations of cell extracts were determined with
a BCA protein assay reagent (Pierce Chemical Co., Rockford, IL).
A typical 50 µl reaction mixture contained 40 mM sodium
cacodylate (pH 6.2), 10 mM MnCl2, 10 mM L-fucose, 5 mM ATP,
101 µM GDP-fucose (∼5000 c.p.m./nmol, mixture of
GDP-[U-14C] fucose from Amersham and GDP-fucose from
Oxford Glycosciences), 5 mM of acceptor substrate (N-acetyllac-
tosamine, lacto N-biose I from Sigma, α2,3-sialyllactosamine or
2-fucosyllactose from Oxford Glycosciences), and 30–60 µg of
protein from cell lysates or 20–30 µl of medium. Controls without
added acceptor were assayed in parallel under the same conditions.
After incubation at 37C for 2 h the reaction mix was diluted with
cold water and applied to a column containing Dowex 1X8–400,
formate form (Kukowska-Latallo et al., 1990). The flow-through
fraction, and 2 ml of a subsequent water elution, were collected and
counted with 1 volume of Instagel (Packard, IL) in a liquid
scintillation counter (Rackbeta 1219, LKB). In the case of
srFuc-TVI, assays were performed essentially as described by
Palcic et al., using LacNAc-octyl as an acceptor and assay
conditions as described above (Palcic et al., 1988). After stopping
the assay with 1 ml of water the assay mixture was loaded on a C18
Sep-Pak cartridge (Waters), washed three times successively with
5 ml water and eluted with 5 ml of methanol.
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